New Brunswick Scientific Co., Inc., Reports Strong Sales and Earnings Growth for 2004 Third Quarter and Nine Months

New Brunswick Scientific Co., Inc., Reports Strong Sales and
Earnings Growth for 2004 Third Quarter and Nine Months 


EDISON, N.J., Oct. 29  /PRNewswire-FirstCall/ -- New Brunswick Scientific Co.,
Inc. (NBS) (NASDAQ:NBSC), today announced sharply improved net sales and higher
net income for the third quarter and nine months ended October 2, 2004, versus
the respective periods of 2003.

Net sales for the third quarter of 2004 rose to $15.2 million from $11.5
million for the comparable 2003 period -- an increase of 32.4% -- with recently
acquired subsidiary RS Biotech contributing $1.1 million to consolidated sales
during the period. Third-quarter net income improved significantly, to a profit
of $234,000, or $0.03 per diluted share, from the year-ago net loss of
$722,000, or $0.08 per share.

For the first nine months of 2004, net sales increased 32.3%, reaching $44.7
million from the $33.8 million reported for the same period one year ago. RS
Biotech increased 2004 nine-month sales by $3.5 million. Net income was
$838,000, or $0.09 per diluted share, compared with the 2003 nine-month net
loss of $2.3 million, or $0.27 per share, which included a pretax gain of
$201,000 on the sale of property.

Gross margin expanded during both the quarterly and nine-month periods due
primarily to the effect of increased absorption of manufacturing overhead
occasioned by the higher sales volumes. Gross margin for the third quarter of
2004 was 39.3%, up from 38.9% in 2003's comparable quarter. For the 2004 nine
months, gross margin was 40.1% versus 35.8% in last year's first nine months.
The margin improvements were partially offset by a $150,000 write-down of
inventory for a discontinued product line during the third quarter.

Selling, general and administrative expenses increased $524,000 and $1.1
million, respectively, for the three- and nine-month periods versus the
comparable year-ago periods, reflecting a previously announced one-time
$346,000 severance payment in the third quarter to the Company's European
Managing Director, the inclusion of the operating expenses of RS Biotech and
foreign translation effects.

Co-founder and Chairman David Freedman said: "Continuing strength in end-market
demand helped to generate solid international and domestic sales growth, with
order intake up more than 26% during the nine months. Volume growth, combined
with significant gross profit expansion, produced the fourth consecutive
quarterly period of solid profitability. Backlog at quarter end stood at $9.3
million, nearly 10% higher than a year ago."

Freedman continued, "The combined effects of the turnaround that began late
last year, successful cost-containment initiatives and new-business synergies
are yielding beneficial results. The commitment of our people to work together
assiduously to manage costs while supporting innovation enables us to continue
to respond rapidly and efficiently to the requirements of emerging technologies
and critical market needs, ensuring our market leadership position."

About New Brunswick Scientific

New Brunswick Scientific Co., Inc., is a leading global provider of a
comprehensive line of research equipment and scientific instrumentation for use
in the life science industry. The company's products are used in the creation,
maintenance and control of physical and biochemical environments required for
the growth, detection and storage of microorganisms for medical, biological and
chemical applications, as well as environmental research and commercial product
development. NBS is a forerunner in the research and development of pioneering
equipment to meet the challenges of new areas of advancement in life science.
Established in 1946, New Brunswick Scientific is headquartered in Edison, New
Jersey, with sales and distribution facilities strategically located in the
United States, Europe and Asia. For more information, please visit
http://www.nbsc.com/.

This document contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995.  Forward-looking statements
may be identified by words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates," "will" or words of similar meaning
and include, but are not limited to, statements about the expected future
business and financial performance of the Company.  Forward- looking statements
are based on management's current expectations and assumptions, which are
inherently subject to uncertainties, risks and changes in circumstances that
are difficult to predict.  Actual outcomes and results may differ materially
from these expectations and assumptions due to changes in global political,
economic, business, competitive, market, regulatory and other factors.  The
Company undertakes no obligation to publicly update or review any
forward-looking information, whether as a result of new information, future
developments or otherwise.

           NEW BRUNSWICK SCIENTIFIC CO., INC., AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per-share amounts)
                               (Unaudited)

                                 Three Months Ended      Nine Months Ended
                                 Oct. 2,   Sept. 27,    Oct. 2,   Sept. 27,
                                   2004       2003        2004       2003

  Net sales                      $15,192    $11,478     $44,719    $33,810
  Operating costs and expenses:
    Cost of sales                  9,223      7,009      26,797     21,693
    Selling, general and
     administrative expenses       4,540      4,016      13,243     12,165
    Research, development and
     engineering expenses            902        775       2,778      2,526

  Total operating costs
   and expenses                   14,665     11,800      42,818     36,384

  Income (loss) from operations      527       (322)      1,901     (2,574)
  Other income (expense):
    Interest income                   22         12          57         49
    Interest expense                (165)      (114)       (500)      (334)
    Other, net                        (1)       (35)        (70)        95
                                    (144)      (137)       (513)      (190)
  Income (loss) before income
   tax expense (benefit)             383       (459)      1,388     (2,764)

  Income tax expense (benefit)       149        263         550       (415)
  Net income (loss)                 $234      $(722)       $838    $(2,349)
  Basic net income
   (loss) per share                $0.03     $(0.08)      $0.10     $(0.27)
  Diluted net income
   (loss) per share                $0.03     $(0.08)      $0.09     $(0.27)

  Basic weighted average
   number of shares outstanding    8,768      8,606       8,709       8,584
  Diluted weighted average
   number of shares outstanding    8,899      8,606       8,857       8,584


                SELECTED CONSOLIDATED BALANCE SHEET ITEMS
                          (Dollars in thousands)
                               (Unaudited)

                                          October 2, 2004  December 31, 2003

  Cash and cash equivalents                    $9,782           $10,536
  Accounts receivable, net                     10,293            10,012
  Inventories                                  13,935            12,304
  Property, plant and equipment, net            6,157             6,478
  Total assets                                 52,359            51,321
  Accounts payable and accrued expenses         7,561             7,260
  Long-term debt, net of current installments   7,091             7,675
  Shareholders' equity                         33,713            31,859
  Working capital                              26,161            25,279
  Current ratio                              3.8 to 1          3.8 to 1


DATASOURCE: New Brunswick Scientific Co., Inc.



CONTACT:  Samuel Eichenbaum, Vice President, Finance and Treasurer, New

Brunswick Scientific Co., Inc., [phone], ; or Matthew J.

Dennis, CFA, NBS Investor Relations, Clear Perspective Group, LLC,

[phone], , for New Brunswick Scientific Co., Inc.



Web site:  http://www.nbsc.com/ 

Copyright